• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • EyePoint Announces First Patient Dosed in Trial of EYP-1901 for Wet AMD americanpharmaceuticalreview
    February 03, 2021
    EyePoint Pharmaceuticals announced that the first patient has been dosed in the Phase 1 clinical trial of EYP-1901 as a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration (wet AMD).
  • EyePoint Reports Positive Results from GLP Toxicology Study of EYP-1901 americanpharmaceuticalreview
    December 24, 2020
    EyePoint Pharmaceuticals announced positive results from its good laboratory practice (GLP) preclinical toxicology study of EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment using its proprietary bioerodible Durasert® ...

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service